Biotech Values

[friendofthedevil]

The problem with it is that it smacks of data mining. We had been discussing moving the median survival upwards with TNFerade. All other trials we were comparing the current SOC with were discussed in terms of median survival. No other drug combination was discussed in any other terms. I have look at dozens of trials and I don't remember one discussion that didn't center around median survival.

Can anyone name a drug that was approved by FDA that didn't increase median survival AND didn't increase cure rate?

So, how important is that hazard ratio - if it were to hold until the end of the trial? (big if)